Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Taxes: 2011-2025

Historic Change in Taxes for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to -$21,000.

  • Anika Therapeutics' Change in Taxes fell 101.69% to -$21,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$372,000, marking a year-over-year decrease of 137.58%. This contributed to the annual value of $665,000 for FY2024, which is 25.47% up from last year.
  • Per Anika Therapeutics' latest filing, its Change in Taxes stood at -$21,000 for Q3 2025, which was up 95.17% from -$435,000 recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Change in Taxes peaked at $1.3 million during Q2 2022, and registered a low of -$1.2 million during Q1 2021.
  • For the 3-year period, Anika Therapeutics' Change in Taxes averaged around $66,000, with its median value being -$13,000 (2025).
  • Per our database at Business Quant, Anika Therapeutics' Change in Taxes slumped by 848.19% in 2021 and then soared by 800.00% in 2024.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Change in Taxes stood at -$888,000 in 2021, then surged by 214.19% to $1.0 million in 2022, then slumped by 58.38% to $422,000 in 2023, then slumped by 77.01% to $97,000 in 2024, then tumbled by 101.69% to -$21,000 in 2025.
  • Its last three reported values are -$21,000 in Q3 2025, -$435,000 for Q2 2025, and -$13,000 during Q1 2025.